1.17
0.02 (1.74%)
| Previous Close | 1.15 |
| Open | 1.19 |
| Volume | 34,103 |
| Avg. Volume (3M) | 41,106 |
| Market Cap | 3,703,997 |
| Price / Sales | 2.19 |
| Price / Book | 5.59 |
| 52 Weeks Range | |
| Earnings Date | 12 Aug 2025 - 18 Aug 2025 |
| Operating Margin (TTM) | -1,378.09% |
| Diluted EPS (TTM) | -12.28 |
| Quarterly Revenue Growth (YOY) | 5,268.80% |
| Total Debt/Equity (MRQ) | 13.66% |
| Current Ratio (MRQ) | 1.03 |
| Operating Cash Flow (TTM) | -11.62 M |
| Levered Free Cash Flow (TTM) | -7.73 M |
| Return on Assets (TTM) | -176.75% |
| Return on Equity (TTM) | -714.97% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Bearish | Bearish |
| Biotechnology (Global) | Bearish | Bearish | |
| Stock | Sonnet BioTherapeutics Holdings | Mixed | Bullish |
AIStockmoo Score
| Analyst Consensus | 1.5 |
| Insider Activity | NA |
| Price Volatility | -2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | -0.5 |
| Average | 0.00 |
|
Sonnet BioTherapeutics Holdings Inc is a clinical-stage biotechnology company. The Company views its operations and manages its business in one segment. The company has developed FHAB (Fully Human Albumin Binding) technology which is well suited for drug development across a range of human disease areas, including in oncology, autoimmune, pathogenic, inflammatory, and hematological conditions. The firm's pipeline products include SON-080 (low-dose IL-6), SON-1210 (IL15- FHAB-IL12), SON-1010 (IL12-FHAB), and others. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Value |
| % Held by Insiders | 1.53% |
| % Held by Institutions | 5.24% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Carolina Wealth Advisors, Llc | 31 Dec 2024 | 32 |
| 52 Weeks Range | ||
| Median | 20.00 (1,609.40%) | |
| Total | 1 Buy | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Chardan Capital | 07 Apr 2025 | 20.00 (1,609.40%) | Buy | 1.20 |
| 28 Mar 2025 | 20.00 (1,609.40%) | Buy | 1.31 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 01 May 2025 | Announcement | Sonnet Chief Medical Officer, Richard Kenney, M.D., to Present at the 6th Annual Cytokine-Based Drug Development Summit |
| 16 Apr 2025 | Announcement | Sonnet Releases Virtual Investor "What This Means" Segment |
| 04 Apr 2025 | Announcement | Sonnet’s SON-1010 Demonstrates a Strong Safety Profile in Combination with Atezolizumab for Treatment of Platinum-Resistant Ovarian Cancer, Including a Partial Response at the Highest Dose |
| 01 Apr 2025 | Announcement | Sonnet Announces the Passing of Founder and CEO Pankaj Mohan, Ph.D. |
| 01 Apr 2025 | Announcement | Sonnet Announces Release of Corporate Update Video |
| 26 Mar 2025 | Announcement | Sonnet BioTherapeutics Successfully Completes First Safety Review of SON-1010 in Combination with Trabectedin in Certain Sarcomas |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |